top of page
NCT05347485
NCT05014646
7A2E19FA-5F33-4045-B0B2-693BD4E6948A
NCT05347485
1/24
Multiple Myeloma Clinical Trials Currently Recruiting
2022 - NCT05463939
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma
2022 - NCT05347485
Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
2021 - NCT05014646
Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
2021 - NCT04892446
Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM
2021 - NCT04855136
Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
2021 - NCT04824794
Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
2021 - NCT04822337
Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma
2021 - NCT04771078
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial
2021 - NCT04770402
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
2021 - NCT04722146
Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
2019 - NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - NCT04113018
Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
2019 - NCT04108195
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
2019 - NCT04071457
Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
2019 - NCT03933735
Phase 1: ABBV-383 (TNB-383B) in Subjects With Relapsed or Refractory Multiple Myeloma
2019 - NCT03901963
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
2018 - NCT03773107
Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM
2018 - NCT03763370
Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Myeloma
2018 - NCT03732703
Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
2018 - NCT03601078
Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
2017 - NCT03215030
Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
2016 - NCT02884102
MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
2016 - NCT02773030
Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
2016 - NCT02693535
Phase 2: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs
bottom of page